Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

AngioDynamics co-founder to lead Delcath

This article was originally published in Clinica

  • News

Executive Summary

Liver cancer treatment specialist Delcath Systems has appointed Eamonn Hobbs president and CEO. Mr Hobbs will bring to the New York firm over 25 years' experience in interventional radiology, interventional cardiology and gastroenterology device industries. He co-founded AngioDynamics, where he was president and CEO until earlier this year. Mr Hobbs succeeds Richard Taney, who will continue to serve on Delcath's board of directors. The company is developing a system designed to deliver ultra-high doses of anti-cancer drugs to the liver, while preventing systemic side-effects associated with chemotherapy. It is currently enrolling patients in phase 2 and 3 clinical studies for treatment of liver cancers using melphalan.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

See All
UsernamePublicRestriction

Register

MT043749

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By